FEELM
14.5.2023 17:06:34 CEST | Business Wire | Press release
FEELM launched its new innovative disposable vape solution FEELM Max, at the Vaper Expo UK 2023 in Birmingham on May 13.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005039/en/
Johnny Zhang, The Assistant President at FEELM (Photo: Business Wire)
As a leading vaping technology provider and flagship brand of atomization tech company SMOORE, FEELM unveiled the advanced FEELM Max solution which boasts three major breakthroughs: the advanced heating technology of the Ceramic Coil S1, a constant power control system and mindful design.
With the first products featuring the FEELM Max solution about to launch in the UK and EU markets, the launch was attended by many top level representatives from many client companies including BAT, RELX International, Totally Wicked, and KIWI.
Setting New 800-Puff Benchmark for 2 ML E-Liquid
The coil technology journey began with first-generation cotton wick coils, progressed to second-generation cotton mesh coil, and has now developed into the era of third-generation ceramic coil technology with the FEELM Max being the latest manifestation of this industry innovation.
Designed to deliver a superior vaping experience, the innovative FEELM Ceramic Coil S1 brings cutting-edge coil technology that offers an increased puff count, setting a new benchmark in the market.
Benefitting from its cotton-free design and the resulting improvement of e-liquid utilization, the FEELM Max is able to boost puff count by more than 30% compared to cotton coil disposable solutions, providing 800 more puffs and setting a new benchmark for 2ml. This innovation allows products using the FEELM Ceramic Coil S1 to offer increased puff counts while remaining totally compliant with all local regulations.
In addition, the new S1 coil decreases the amount of impurities from the heating process by 78%, resulting in fresher breath and no unpleasant aftertaste. This is a significant stride towards ensuring a clean and silky vaping experience for consumers.
Electronic and Design Breakthroughs
The FEELM Max solution uses a constant power energy management system for stable vaping and over 95% vapor consistency. This technology improves taste consistency by 35%, which further enhances the user experience.
FEELM Max products showcase a transparent e-liquid tank for both aesthetics and user convenience. No longer will vapers have to guess how much e-liquid is left in their device because one quick look will let them know. The CMF Lab refines this design through specialized research and has developed a scientific ergonomic model for the vaping industry.
First Industrial End-To-End Whole-Chain Recycling Scheme
FEELM has also launched the first industrial whole-chain recycling scheme, collaborating with RELX International in the UK. Conscious of the potential harm of vapes ending up in landfills, FEELM has taken the responsibility for implementing a scheme that will facilitate vape recycling to a fuller extent, thereby minimising the environmental impact.
The company's commitment to making recycling more accessible demonstrates its dedication to environmental sustainability. As the initiative gains traction, it could serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in sustainability efforts.
Shaping a Sustainable and Compliant Future with Partners
FEELM's success is not solely due to its innovative technology and the relentless pursuit of excellence, but also the strong collaboration it has forged with its clients and industry partners.
Bing Du, the CEO and founder of RELX International stated at the event: “Thanks to the groundbreaking technology of FEELM Max, and driven by our legendary partnership with FEELM, RELX International is on course to revolutionize the vaping experience across the globe.”
Liam Cagliarini, UK CEO of KIWI Vapor, the leading Italian brand, stated: "We aim to collaborate with FEELM on latest technology, and provide a consistency vaping experience for consumers."
Marcus Saxton, CEO of Totally Wicked, top British brand, added: "FEELM’s innovative technology has enhanced the consumer experience. As a partner of FEELM, Totally Wicked shares the responsibility of promoting sustainability in the atomization industry through active participation in the recycling system."
FEELM intends to continue pushing the boundaries of what's possible in vaping technology, while keeping its commitment to sustainability and compliance at the heart of its operations. The company's mission to shape a better vaping industry, not only for today but for generations to come, remains stronger than ever.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005039/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom